We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Drug Development Advance for Treatment of Autoimmune Diseases, Chronic Inflammation Disorders

By LabMedica International staff writers
Posted on 07 Oct 2014
Print article
Image: Crystal structure of the immunoproteasome (Photo courtesy of the department of biochemistry, TUM).
Image: Crystal structure of the immunoproteasome (Photo courtesy of the department of biochemistry, TUM).
The immune system functions as the body’s protectors, defending it from intruders such as bacteria and viruses. However, to ascertain what is happening in the cell, the immune system requires information on the foreign invaders. This chore is taken on by protein complexes called immunoproteasomes. These are cylindrical complexes break down the protein structures of the intruders into fragments that can be used by the defense system. Biochemists in Germany have now discovered a way to suppress its functionality, thereby laying the foundation for possible enhancements of existing drugs.

“In autoimmune disorders like rheumatism, type 1 diabetes, and multiple sclerosis or severe inflammations a significantly increased immunoproteasome concentration can be measured in the cells,” explained Prof. Michael Groll, from the department of biochemistry at Technische Universitaet Muenchen (TUM; Germany). “The deactivation of this degradation machinery suppresses the regeneration of immune signaling molecules, which, in turn, prevents an excessive immune reaction.”

Scientists have vigorously been searching for new active substances that suppress immunoproteasomes in a targeted way without inhibiting the constitutive proteasomes that are also present in cells. Constitutive proteasomes degrade defective or no longer required proteins and are thus responsible for cellular recycling. Notably cell death occurs, when both the constitutive proteasomes and the immunoproteasomes are inactivated.

In early 2012, researchers led by Dr. Groll fulfilled a prerequisite for designing specific active substances: they deciphered the crystal structure of the immunoproteasome, allowing them to target the slight but significant differences between the otherwise almost identical structures. The potential drug that the researchers developed is based on the epoxyketon ONX 0914, an immunoproteasome inhibitor that is undergoing clinical trials. The researchers replaced the epoxyketon with a sulfonyflouride group and changed its positioning on the inhibitor. The result was a new compound that selectively blocks the immunoproteasome without influencing the constitutive proteasome.

First author Christian Dubiella clarified what makes the discovered process so distinctive: “Normally, inhibitors clog up the active center of the enzyme and thereby disable its functionality. The substance synthesized by us, however, attaches to its target, causing the active center to destroy itself, and then gets detached after successful inactivation.”
Using X-ray structure analysis, clues into the atomic mechanisms were discovered, paving the way for personalized development of immunoprotease inhibitors, thus helping develop a future generation of drugs, according to the scientists.

The study’s findings were published online September 22, 2014, in the journal Angewandte Chemie International Edition.

Related Links:

Technische Universitaet Muenchen


New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Vitamin B12 Test
CHORUS CLIA VIT B12
New
Newborn Screening Test
NeoMass AAAC 3.0

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.